Triazolyl thioamide derivates
    3.
    发明授权
    Triazolyl thioamide derivates 失效
    三唑氧化物衍生物

    公开(公告)号:US5175163A

    公开(公告)日:1992-12-29

    申请号:US617126

    申请日:1990-11-21

    CPC分类号: C07D249/14

    摘要: The invention relates to novel triazolyl thioamides of the general formula (I), ##STR1## wherein Q represents hydrogen or a heterocyclic group optionally bearing one or more C.sub.1-4 alkyl substituent(s), or a group of the formula SR.sup.1, whereinR.sup.1 stands for straight or branched chained alkyl group comprising 1 to 6 carbon atom(s), or a group of the formula NR.sup.2 R.sup.3, whereinR.sup.2 and R.sup.3 each represent hydrogen, straight or branched chained C.sub.1-4 alkyl or C.sub.2-6 alkenyl group,Y denotes C.sub.1-4 alkyl optionally bearing one or more hydroxyl or C.sub.1-4 alkoxy substituent(s), phenyl-(C.sub.1-4 alkyl) optionally bearing on the phenyl ring one or more C.sub.1-4 alkoxy group(s), or phenoxy-(C.sub.1-4 alkyl) optionally substituted on the phenyl ring by a C.sub.1-4 alkyl bearing a heterocyclic group containing a nitrogen atom,and pharmaceutically acceptable acid addition salts thereof.Furthermore the invention relates to a process for preparing these compounds.The compounds according to the invention possess tranquillant, antidepressant, spacmolytic, antiinflammatory, analgesic and antiperistaltic effects.

    摘要翻译: 本发明涉及通式(I)的新型三唑基硫代酰胺,其中Q表示氢或任选带有一个或多个C 1-4烷基取代基的杂环基或式SR 1的基团 其中R1代表包括1至6个碳原子的直链或支链烷基或式NR2R3基团,其中R2和R3各自表示氢,直链或支链C 1-4烷基或C 2-6烯基 基团,Y表示任选带有一个或多个羟基或C 1-4烷氧基取代基的C 1-4烷基,任选地在苯环上带有一个或多个C 1-4烷氧基的苯基 - (C 1-4烷基) 或在苯环上被含有含有氮原子的杂环基的C 1-4烷基任选取代的苯氧基 - (C 1-4烷基)及其药学上可接受的酸加成盐。 此外,本发明涉及一种制备这些化合物的方法。 根据本发明的化合物具有镇静,抗抑郁,间质,抗炎,止痛和抗静脉作用。

    Novel triazolo-pyrimidine derivatives
    5.
    发明授权
    Novel triazolo-pyrimidine derivatives 失效
    新型三唑衍生物衍生物

    公开(公告)号:US5064826A

    公开(公告)日:1991-11-12

    申请号:US487412

    申请日:1990-03-02

    CPC分类号: C07D495/14

    摘要: This invention relates to novel triazolopyrimidine derivatives of formulae (Ia) and (Ib), ##STR1## wherein Q represents hydrogen, a heterocyclic group optionally substituted by a C.sub.1-4 alkyl group and containing one or more oxygen and/or nitrogen atoms or a group of formula--SR.sup.1 wherein R.sup.1 is alkyl or aralkyl, or a group of formula--NR.sup.2 R.sup.3 wherein R.sup.2 and R.sup.3 are independently hydrogen, alkyl, alkenyl, cycloalkyl, aralkyl, aryl or a heterocyclic group,m and n are independently 0, 1, 2, 3 or 4, with the provision that if m stands for 0, then n is different from 0, and if both n and m are 1 or m stands for 0 and n is 2, the Q is different from methylthio or morpholino group, their mixtures or pharmaceutically acceptable salts. Furthermore, the invention relates to a process for preparing these compounds.The compounds of formulae (Ia) and (Ib) are able to inhibit the ptosis caused by tetrabenazine and they have analgetic activity.

    摘要翻译: 本发明涉及式(Ia)和(Ib)的新型三唑并嘧啶衍生物,其中Q表示氢,任选被C 1-4烷基取代并含有一个或多个氧和/ 或氮原子或式-SR1的基团,其中R 1是烷基或芳烷基,或式-NR 2 R 3基团,其中R 2和R 3独立地是氢,烷基,烯基,环烷基,芳烷基,芳基或杂环基,m和n是 独立地0,1,2,3或4,条件是如果m代表0,则n不同于0,并且如果n和m都是1或m代表0并且n是2,则Q不同 甲硫基或吗啉代基,它们的混合物或药学上可接受的盐。 此外,本发明涉及一种制备这些化合物的方法。 式(Ia)和(Ib)的化合物能够抑制由丁苯那嗪引起的下垂并具有止痛活性。

    5-(substituted amino)-1,2,4-triazolo (1,5-A) pyrimidine derivatives
    6.
    发明授权
    5-(substituted amino)-1,2,4-triazolo (1,5-A) pyrimidine derivatives 失效
    5-(取代氨基)-1,2,4-三唑并(1,5-A)嘧啶衍生物

    公开(公告)号:US5478825A

    公开(公告)日:1995-12-26

    申请号:US261214

    申请日:1994-06-15

    摘要: The disclosed compounds have the formula ##STR1## wherein Q is a 6-membered saturated heterocyclic group or a group S(O)pR.sup.3, whereinp is 0, 1, or 2, andR.sup.3 is alkyl, alkenyl, or phenyl-, which may have halogen or nitro substituents, or phenyl optionally substituted;or NR.sup.4 R.sup.5 whereinR.sup.4 and R.sup.5 are hydrogen, alkyl, alkenyl, phenyl-alkyl, or di-alkyl-amino-alkyl;R.sup.1 and R.sup.2 are hydrogen or alkyl, ortogether form a group (CH.sub.2)n--Y--(CH.sub.2)m, wherein Y is CH.sub.2, or NR.sup.6, wherein R.sup.6 is phenyl-alkyl,n and m are 0 or 1 to 5;Z is NR.sup.7 R.sup.8, whereinR.sup.7 and R.sup.8 each are hydrogen, alkenyl, cycloalkyl, adamantayl, or phenyl-alkyl, which may have one or more substituents ortogether form a group of (CH.sub.2)j--W--(CH.sub.2)k, wherein j and k each are 1 to 3, and W is oxygen, CH.sub.2, CHOH, or NR.sup.10 , wherein R.sup.10 is hydrogen, alkoxycarbonyl, or alkyl, which latter may be substituted.or SR.sup.9, whereinR.sup.9 is alkyl substituted by alkoxy-carbonyl and possess inotropic and antianginal effects, complemented by antiinflammatory, ulcus, and gastric acid secretion inhibiting, and by weaker tranquillant, spasmolytic, and analgesic properties.

    摘要翻译: 所公开的化合物具有式“IMAGE”,其中Q为6元饱和杂环基团或S(O)pR 3基团,其中p为0,1或2,R 3为烷基,烯基或苯基,其中 可以具有卤素或硝基取代基,或任选取代的苯基; 或NR4R5,其中R4和R5是氢,烷基,烯基,苯基 - 烷基或二 - 烷基 - 氨基 - 烷基; 或者一起形成基团(CH 2)n -Y-(CH 2)m,其中Y是CH 2或NR 6,其中R 6是苯基 - 烷基,n和m是0或1至5; Z是NR7R8,其中R7和R8各自是氢,烯基,环烷基,金刚烷基或苯基 - 烷基,其可以具有一个或多个取代基或一起形成(CH 2)j W-(CH 2)k的基团,其中j和k 各自为1至3,W为氧,CH 2,CHOH或NR 10,其中R 10为氢,烷氧基羰基或烷基,后者可以被取代。 - 或SR9,其中R9是被烷氧基 - 羰基取代的烷基,并且具有各向同性和抗心绞痛作用,由抗炎,溃疡和胃酸分泌抑制以及较弱的镇静剂,解痉药和镇痛药物补充。